HeXun Biosciences Co., Ltd. (TPEX:6986)
Taiwan · Delayed Price · Currency is TWD 41.30
-0.20 (-0.48%)
Sep 8, 2026, 1:30 PM CST
HeXun Biosciences Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,153 | 2,898 | 3,105 | 2,981 | - | - | |
Market Cap Growth | -30.66% | -6.67% | 4.17% | - | - | - |
Enterprise Value | 1,359 | 2,440 | 2,861 | 2,763 | - | - |
Last Close Price | 41.30 | 62.72 | 67.20 | 64.51 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.38 | 25.90 | 21.09 | 89.01 | - | - |
PS Ratio | 6.99 | 9.88 | 10.84 | 22.83 | - | - |
PB Ratio | 2.01 | 3.91 | 5.00 | 6.30 | - | - |
P/TBV Ratio | 2.05 | 4.02 | 5.23 | 6.79 | - | - |
P/FCF Ratio | 16.00 | 21.21 | 37.13 | 132.95 | - | - |
P/OCF Ratio | 13.15 | 17.68 | 25.68 | 69.18 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.41 | 8.32 | 9.99 | 21.16 | - | - |
EV/EBITDA Ratio | 8.48 | 17.22 | 16.27 | 64.08 | - | - |
EV/EBIT Ratio | 10.41 | 20.67 | 18.37 | 100.94 | - | - |
EV/FCF Ratio | 10.10 | 17.86 | 34.21 | 123.24 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.05 | 0.06 | 0.15 | 0.23 | 0.35 |
Debt / EBITDA Ratio | 0.22 | 0.25 | 0.20 | 1.56 | 13.75 | - |
Debt / FCF Ratio | 0.26 | 0.27 | 0.42 | 3.24 | 7.16 | - |
Net Debt / Equity Ratio | -0.74 | -0.64 | -0.55 | -0.54 | -0.38 | -0.05 |
Net Debt / EBITDA Ratio | -5.09 | -3.34 | -1.92 | -5.96 | -46.59 | 0.26 |
Net Debt / FCF Ratio | -5.90 | -3.46 | -4.04 | -11.46 | -12.01 | 0.31 |
Asset Turnover | 0.31 | 0.38 | 0.45 | 0.27 | 0.14 | - |
Inventory Turnover | 2.38 | 2.50 | 2.55 | - | - | - |
Quick Ratio | 11.70 | 9.35 | 8.52 | 11.67 | 9.82 | 10.87 |
Current Ratio | 12.14 | 9.75 | 8.99 | 12.05 | 10.55 | 11.94 |
Return on Equity (ROE) | 13.26% | 16.43% | 26.92% | 8.50% | -1.96% | - |
Return on Assets (ROA) | 8.31% | 9.55% | 15.23% | 3.51% | -1.61% | - |
Return on Invested Capital (ROIC) | 39.60% | 38.05% | 56.92% | 13.32% | -4.50% | -24.86% |
Return on Capital Employed (ROCE) | 11.90% | 15.20% | 23.80% | 5.10% | -2.30% | -17.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.40% | 3.86% | 4.74% | 1.12% | - | - |
FCF Yield | 6.25% | 4.71% | 2.69% | 0.75% | - | - |
Dividend Yield | 0.53% | 0.35% | - | - | - | - |
Buyback Yield / Dilution | -0.26% | 0.03% | -1.61% | -20.81% | -22.92% | - |
Total Shareholder Return | 0.27% | 0.38% | -1.61% | -20.81% | -22.92% | - |